News
-
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial featuring patient-tailored microperimetry for geographic atrophy studies at EURETINA 2026 -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101
Galimedix establishes a Scientific Advisory Board for Alzheimer's disease to guide the development of GAL-101, a novel oral drug candidate, with global experts providing expertise in Phase 2 clinical-stage biotechnology -
